DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with ...
The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period.PD-L1 ...
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback